Demonstrating efficacy of T-DXd outside the classically defined HER2-overexpressing/HER2-amplified tumors and across a broad spectrum of tumor types (e.g. breast, gastric, lung, colorectal) would represent a paradigm shift for HER2-targeted therapies. This evidence concerns the gene ERBB2 and neoplasm.